JP2002521329A - フェニルアセチルグルタミン、フェニルアセチルイソグルタミンおよび/または酢酸フェニルの投与のための治療管理 - Google Patents

フェニルアセチルグルタミン、フェニルアセチルイソグルタミンおよび/または酢酸フェニルの投与のための治療管理

Info

Publication number
JP2002521329A
JP2002521329A JP2000560887A JP2000560887A JP2002521329A JP 2002521329 A JP2002521329 A JP 2002521329A JP 2000560887 A JP2000560887 A JP 2000560887A JP 2000560887 A JP2000560887 A JP 2000560887A JP 2002521329 A JP2002521329 A JP 2002521329A
Authority
JP
Japan
Prior art keywords
formula
compound
group
pharmaceutical composition
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000560887A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002521329A5 (https=
Inventor
スタニスロー、アール、バージンスキー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2002521329A publication Critical patent/JP2002521329A/ja
Publication of JP2002521329A5 publication Critical patent/JP2002521329A5/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2000560887A 1998-07-23 1999-07-02 フェニルアセチルグルタミン、フェニルアセチルイソグルタミンおよび/または酢酸フェニルの投与のための治療管理 Pending JP2002521329A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/121,567 1998-07-23
US09/121,567 US6258849B1 (en) 1998-07-23 1998-07-23 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
PCT/US1999/015017 WO2000004894A2 (en) 1998-07-23 1999-07-02 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010228241A Division JP2011051993A (ja) 1998-07-23 2010-10-08 フェニルアセチルグルタミン、フェニルアセチルイソグルタミンおよび/または酢酸フェニルの投与のための治療管理

Publications (2)

Publication Number Publication Date
JP2002521329A true JP2002521329A (ja) 2002-07-16
JP2002521329A5 JP2002521329A5 (https=) 2006-08-17

Family

ID=22397538

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000560887A Pending JP2002521329A (ja) 1998-07-23 1999-07-02 フェニルアセチルグルタミン、フェニルアセチルイソグルタミンおよび/または酢酸フェニルの投与のための治療管理
JP2010228241A Withdrawn JP2011051993A (ja) 1998-07-23 2010-10-08 フェニルアセチルグルタミン、フェニルアセチルイソグルタミンおよび/または酢酸フェニルの投与のための治療管理

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010228241A Withdrawn JP2011051993A (ja) 1998-07-23 2010-10-08 フェニルアセチルグルタミン、フェニルアセチルイソグルタミンおよび/または酢酸フェニルの投与のための治療管理

Country Status (20)

Country Link
US (2) US6258849B1 (https=)
EP (1) EP1098643B1 (https=)
JP (2) JP2002521329A (https=)
KR (4) KR100399658B1 (https=)
CN (3) CN100400039C (https=)
AT (1) ATE257378T1 (https=)
AU (1) AU759278B2 (https=)
BR (1) BR9912356A (https=)
CA (1) CA2336945C (https=)
DE (1) DE69914084T2 (https=)
DK (1) DK1098643T3 (https=)
EA (1) EA004179B1 (https=)
ES (1) ES2214866T3 (https=)
ID (1) ID28160A (https=)
IL (1) IL140848A (https=)
NZ (1) NZ509244A (https=)
PL (1) PL213698B1 (https=)
PT (1) PT1098643E (https=)
WO (1) WO2000004894A2 (https=)
ZA (1) ZA200100622B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127419A (en) * 1998-11-23 2000-10-03 Burzynski; Stanislaw R. Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis
DK1313697T3 (da) 2000-08-29 2006-04-10 Nobex Corp Immunregulatoriske forbindelser, derivater deraf samt anvendelse deraf
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US7087219B2 (en) * 2003-05-28 2006-08-08 Stanislaw R. Burzynski Toothpaste containing anticancer agents
US20060246016A1 (en) * 2003-05-28 2006-11-02 Burzynski Stanislaw R Toothpaste containing anticancer agents
US7772108B2 (en) * 2004-06-25 2010-08-10 Samsung Electronics Co., Ltd. Interconnection structures for semiconductor devices and methods of forming the same
DK1773767T3 (en) 2004-07-07 2016-03-21 Biocon Ltd Synthesis of azo bound in immune regulatory relations
US20060058383A1 (en) * 2004-07-28 2006-03-16 Peng Huang Propyl 3-bromo-2-oxopropionate and derivatives as novel anticancer agents
SI2153870T1 (sl) * 2004-11-26 2014-05-30 Ucl Business Plc Sestavki, ki obsegajo ornitin in fenilacetat ali fenilbutirat, za zdravljenje hepatitične encefalopatije
US20060205818A1 (en) * 2005-03-08 2006-09-14 Burzynski Stanislaw R Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives
HUE035921T2 (en) 2009-04-03 2018-05-28 Ocera Therapeutics Inc L-ornithine phenyl acetate and methods of making thereof
CN104434894A (zh) 2009-06-08 2015-03-25 Ucl商业有限公司 使用l-鸟氨酸苯乙酸盐治疗门静脉高压和恢复肝功能
US8946473B2 (en) 2010-10-06 2015-02-03 Ocera Therapeutics, Inc. Methods of making L-ornithine phenyl acetate
ES2769000T3 (es) 2014-11-24 2020-06-24 Ucl Business Ltd Tratamiento de enfermedades asociadas con la activación de células estrelladas hepáticas utilizando terapias reductoras de amoníaco
WO2017031131A1 (en) 2015-08-18 2017-02-23 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
JP6861708B2 (ja) * 2015-12-30 2021-04-21 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 除脂肪体重を測定するための方法
US10624869B2 (en) 2017-05-08 2020-04-21 Stanislaw R. Burzynski Methods for the treatment of recurrent glioblastoma (RGBM)
MX389665B (es) 2017-05-11 2025-03-20 Ocera Therapeutics Inc Procesos para producir fenilacetato de l-ornitina
AU2018282735A1 (en) * 2017-06-12 2020-02-06 Stanislaw R. Burzynski Methods for the treatment of leptomeningeal disease
US11344521B2 (en) 2017-06-12 2022-05-31 Burzynski Research Institute, Inc. Methods for the treatment of leptomeningeal disease
US20230190694A1 (en) * 2021-11-03 2023-06-22 Stanislaw R. Burzynski Compositions for and methods of precision cancer treatment
CN116019798B (zh) * 2022-07-20 2024-03-12 中南大学湘雅二医院 苯乙酰谷氨酰胺在制备预防和/或治疗阿霉素所致心脏毒性的药物中的应用
CN116491472B (zh) * 2022-12-14 2024-07-26 上海交通大学医学院附属第九人民医院 苯乙酰谷氨酰胺在构建慢性创面动物模型中的用途
EP4731793A2 (en) * 2023-06-21 2026-04-29 Stanislaw R. Burzynski Compositions comprising antineoplastons and methods of treating pancreatic cancer
EP4731792A2 (en) * 2023-06-21 2026-04-29 Stanislaw R. Burzynski Compositions comprising antineoplastons and methods of treating lung cancer
WO2024263963A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating head and neck cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4470970A (en) * 1981-07-02 1984-09-11 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
US5254587A (en) * 1990-09-04 1993-10-19 Burzynski Stanislaw R Methods for treating AIDS
WO1993024123A1 (en) * 1992-05-27 1993-12-09 Burzynski Stanislaw R Methods for treating viral infections
US5605930A (en) * 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
ATE310505T1 (de) 1996-05-14 2005-12-15 Stanislaw R Burzynski Liposomale antineoplaston therapie mit bemerkenswert verbesserter antineoplastischer aktivität

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4470970A (en) * 1981-07-02 1984-09-11 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
US5254587A (en) * 1990-09-04 1993-10-19 Burzynski Stanislaw R Methods for treating AIDS
US5605930A (en) * 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
WO1993024123A1 (en) * 1992-05-27 1993-12-09 Burzynski Stanislaw R Methods for treating viral infections

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CANCER, vol. 75(12), JPN7010001009, 1995, pages 2932 - 2938, ISSN: 0001588447 *
DRUGS EXPTL. CLIN. RES., vol. 12(SUPPL.1), JPN6010018058, 1986, pages 47 - 55, ISSN: 0001588444 *
DRUGS EXPTL. CLIN. RES., vol. 12(SUPPL.1), JPN6010018059, 1986, pages 17 - 24, ISSN: 0001588445 *
DRUGS EXPTL. CLIN. RES., vol. 12(SUPPL.1), JPN6010018060, 1986, pages 25 - 35, ISSN: 0001588446 *
KURUME MED. J., vol. 43(2), JPN6010019244, 1996, pages 137 - 147, ISSN: 0001588443 *

Also Published As

Publication number Publication date
KR100399658B1 (ko) 2003-09-29
KR20010071025A (ko) 2001-07-28
CN1660061A (zh) 2005-08-31
EP1098643B1 (en) 2004-01-07
KR100417101B1 (ko) 2004-02-05
DE69914084D1 (de) 2004-02-12
WO2000004894A3 (en) 2000-04-27
ES2214866T3 (es) 2004-09-16
US6943192B2 (en) 2005-09-13
KR20030027088A (ko) 2003-04-03
CN1605334A (zh) 2005-04-13
CA2336945A1 (en) 2000-02-03
IL140848A0 (en) 2002-02-10
ZA200100622B (en) 2002-06-26
AU4854299A (en) 2000-02-14
PT1098643E (pt) 2004-05-31
AU759278B2 (en) 2003-04-10
NZ509244A (en) 2004-02-27
EP1098643A2 (en) 2001-05-16
EA200100168A1 (ru) 2001-08-27
KR20030027087A (ko) 2003-04-03
DE69914084T2 (de) 2004-10-28
KR100414587B1 (ko) 2004-01-13
JP2011051993A (ja) 2011-03-17
DK1098643T3 (da) 2004-05-24
WO2000004894A2 (en) 2000-02-03
HK1037142A1 (en) 2002-02-01
CN1191064C (zh) 2005-03-02
PL213698B1 (pl) 2013-04-30
US20010044466A1 (en) 2001-11-22
BR9912356A (pt) 2001-04-17
KR100417100B1 (ko) 2004-02-05
ATE257378T1 (de) 2004-01-15
IL140848A (en) 2005-05-17
ID28160A (id) 2001-05-10
PL345959A1 (en) 2002-01-14
CA2336945C (en) 2008-11-18
CN1319010A (zh) 2001-10-24
CN100400039C (zh) 2008-07-09
US6258849B1 (en) 2001-07-10
EA004179B1 (ru) 2004-02-26
KR20030027089A (ko) 2003-04-03

Similar Documents

Publication Publication Date Title
JP2002521329A (ja) フェニルアセチルグルタミン、フェニルアセチルイソグルタミンおよび/または酢酸フェニルの投与のための治療管理
OA11924A (en) Methods for treatment of sickle cell anemia.
JP2002506816A (ja) ケト酸及びアミン誘導体の塩、及び医薬品調製を目的としたそれらの利用
CN104968340A (zh) 治疗肝脏疾病或病状的用途和方法
CN111803489A (zh) 含笑内酯及其衍生物在垂体腺瘤治疗中的应用
US20100087398A1 (en) Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions
US10507228B2 (en) Methods and compositions related to KRAS inhibitors
US4918193A (en) Methods for preparing 3-[N-phenyl-acetylaminopiperidine]-2,6-dion
US7226766B2 (en) S-methylcysteine, S-ethylcysteine, and related S-alkylthiols as antagonists to the effects of S-nitrosothiols and nitric oxide
JP4428481B2 (ja) 神経因性疼痛治療剤
JPH08501796A (ja) イブプロフェン−カフェイン配合物
HK1037142B (en) Phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate for the treatment of neoplastic diseases
MXPA99000255A (en) Treatment regimen for the administration of phenylacetilglutamine, phenylacetilisoglutamine and / or fen acetate
JPS61129124A (ja) 抗腫瘍剤
JPH0149130B2 (https=)
HK1074771A (en) Use of composition in the manufacture of a medicament for treating neoplastic disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060630

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100409

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100709

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100716

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100809

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100816

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100909

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101008

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110812